Skip to main content
Signal8

BioLineRx Ltd. (BLRX) Form 6-K — May 27, 2026

$BLRXForm 6-KFiled May 27, 2026, 7:19 AM ET0001178913-26-002934Original filing

BioLineRx reported a net loss of $2.6 million for Q1 2026, driven by a 56% increase in R&D expenses to $2.5 million as it advances its new GLIX1 program. Revenue rose 87% year-over-year to $0.5 million, primarily from royalties on APHEXDA sales by partner Ayrmid. The company highlighted significant clinical progress, announcing the first patient dosed in the Phase 1/2a trial for GLIX1 in glioblastoma in April 2026. New preclinical data demonstrated potent anti-tumor effects in TMZ-resistant patient-derived xenograft models, supporting the asset's potential in this aggressive cancer type.

Key figures

Revenue
477000
Revenue Yoy
86.7%
Total Assets
40905000
Cash Position
17400000
Rd expenses
2528000
G a expenses
858000
Royalty revenue
477000
Aphexda sales q1
2700000
Aphexda royalty q1
500000
Blackrock loan maturity
December 1, 2027
Tetragon total commitment
5000000
Tetragon investment to date
2600000
Blackrock loan interest rate
9.5%

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    BioLineRx Ltd. (BLRX) Form 6-K — May 27, 2026: AI Analysis | Signal8